Mumbai, May 26 -- On a standalone basis, the company reported a net profit of Rs 64.34 crore in Q4 FY26, down 41.56% YoY but rising 60.17% QoQ.

Revenue from operations declined 31.07% YoY to Rs 234.67 crore in Q4 FY26 due to negligible sales of one molecule in the PI vertical. However, revenue increased 21.96% QoQ from Rs 192.41 crore driven by higher sales of advance contrast media.

The company said the YoY decline in revenue reflected timing-related order phasing in select PI accounts and customer-side inventory normalization. However, management maintained that underlying demand visibility remains strong and expects normalization in upcoming quarters.

Gross profit stood at Rs 132.5 crore in Q4 FY26, down 29.2% YoY but up 33% QoQ. Gr...